We are international

Call the IMF Hotline. We are here for you. The IMF Office is open from 8:00AM - 5:00PM PST, Monday-Friday.

If you have a question, call the IMF InfoLine at (800) 452-CURE (800-452-2873) in the US and Canada. The InfoLine is open from 9:00 - 4:00 PT Monday - Friday. Elsewhere call (818) 487-7455. You can also contact us via the web.
IMF - Home Page
previous     next      view all

ICYMI: Watch the replay of the 2015 Los Angeles Patient & Family Seminar.
Emphasizing education, advocacy and support, the IMF Patient & Family Seminars empower patients and provide invaluable information to the myeloma community. Click here to watch the replay.

Important Update for Myeloma Patients: Selinexor STORM Trials
Selinexor is an orally administered Selective Inhibitor of Nuclear Export, or SINE™, therapy for the treatment of multiple myeloma. Selinexor inhibits the transport of tumor suppressor proteins from the cell nucleus, where they detect cancerous DNA changes and induce cancer cell death. More than 900 patients have been treated with selinexor in phase I and phase II clinical trials and in an ongoing phase I clinical trial, Selinexor in combination with low-dose dexamethasone demonstrated favorable responses. To read more about the Selinexor STORM trials, please click HERE.

Is Precision Medicine What We Need?
In his blog this week, IMF Chariman Dr. Brian Durie compares two opinions on the value of precision medicine as outlined in recent articles in Science and The New England Journal of Medicine. Although precision medicine is popular and ultimately feasible is it the most cost-effective approach to myeloma? he asks. To read Dr. Durie's blog, click HERE.

Proposed "Value Framework" Could Limit Patient Access to Myeloma Drugs
The American Society of Clinical Oncology (ASCO) has created a "Value Framework" in an attempt to balance cancer drug costs with value to the patient. In his blog this week, IMF Chariman Dr. Brian Durie examines the framework's point system. "I believe the proposed system does not work well for myeloma," he writes, "and if implemented could limit needed drug access for myeloma patients." To read Dr. Durie's blog, click HERE.

Can a "Longevity Feast" Be the Key to Longer Life?
In his blog this week, IMF Chairman Dr. Brian Durie discusses a recent New York Times interview with longevity expert Dan Buettner about putting on an Ikarian "Longevity Feast" inspired by his book, The Blue Zones Solution. The book takes a deep dive into five cultures around the world where people have the healthiest and longest lives. While a healthy diet is certainly a cornerstone to vibrant life, Dr. Durie writes that, "spending time with the right mix of friends and family is very important. This natural or organic stress reduction has almost a magical effect." To read the full post, click HERE

The International Myeloma Foundation (IMF) Announces Publication of New Diagnostic Guidelines to Better Assess Patients and Guide Treatment

Revisions to the International Staging System by the IMF’s International Myeloma Working Group Reported in the Journal of Clinical Oncology

Click here to watch the "Advocacy in August: How to Connect with your Representative at Home" replay
With the Congressional August recess in full swing, this webinar will give you the tools to educate your members of Congress on the issues that matter most to you and the multiple myeloma community. Whether you’re new to advocacy or a veteran, this webinar is not to be missed! The presentation will focus on breaking down the advocacy process, helping you understand the issues, and teaching you how to get the most out of the resources available to you. To watch the replay, please click HERE.

Is There a Link Between a Genetic Variation and Poor Myeloma Survival Rate?
In his blog this week, IMF Chairman Dr. Brian Durie comments on news about a multi-institutional study that found patients with multiple myeloma with a genetic variation in the gene FOPNL have poorer outcomes than patients without it. “As one might suspect, much further work is needed to substantiate and understand this finding,” he notes, “but this initial report is quite tantalizing.” To read Dr. Durie’s blog, click HERE

European Medicines Agency Grants Accelerated Assessment of Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted an accelerated assessment to ixazomib, an investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma.

FDA Approves Kyprolis® (Carfilzomib) for Combination Use in the Treatment of Patients with Relapsed Multiple Myeloma

Approval Expands Kyprolis Indication. Patients Treated With Kyprolis in Combination With Standard of Care Lived 50 Percent Longer Without Disease Worsening Compared to Standard of Care Alone in Pivotal Study

previous     next      view all